

Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19

Investigational Agent: Imatinib

Protocol Number: 2038GCCC

HRPO Number: HP-00090890

IND: 149239

NCT: 04394416

Sponsor:

Andrea R. Levine, M.D., M.S.

Protocol Version: 3

January 31, 2024

CONFIDENTIAL

The information contained in this protocol is confidential and is intended for the use of the clinical investigators and their study staff. The information in this document is the property of University of Maryland Baltimore, and may not be disclosed unless federal or state law or regulations require such disclosure. This information may be disclosed only to those persons involved in the study who have a need to know, with the obligation not to further disseminate this information.

Key Personnel

Principal Investigator:

Andrea R. Levine, M.D., M.S.
Assistant Professor of Medicine
University of Maryland School of Medicine
Division of Pulmonary & Critical Care Medicine
419 West Redwood Street, Suite 600
Baltimore, MD 21201
Telephone: 410-328-8141
Fax: 410-328-0177
E-mail: andrea.levine@som.umaryland.edu

Co-Investigator:

Joel V. Chua, M.D.
Assistant Professor of Medicine
Chief, Surgical Infectious Disease, UMMC
University of Maryland School of Medicine, Institute of Human Virology
725 West Lombard Street, Room N146
Baltimore, MD 21201
Telephone: 410-706-5704
Fax: 410-706-3243
Email: jchua@ihv.umaryland.edu

Rohit Talwani, M.D.
Associate Professor of Medicine
University of Maryland School of Medicine, Institute of Human Virology
725 West Lombard Street
Baltimore, MD 21201
Telephone: 410-706-8264
Fax: 410-706-4619
E-mail: rtalwani@ihv.umaryland.edu

Nirav G. Shah, M.D.
Associate Professor of Medicine
University of Maryland School of Medicine
Division of Pulmonary & Critical Care Medicine
419 West Redwood Street, Suite 600
Baltimore, MD 21201
Telephone: 410-328-8141
Fax: 410-328-0177
E-mail: Andrea. ngshah@som.umaryland.edu

Statistician: Søren Bentzen, Ph.D., D.Sc.

Lead Protocol Coordinator: Larissa Sanglard , Email: Larissa.Sanglard@umm.edu

Protocol Synopsis

Title: Randomized Double-Blind, Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19.

Study Phase: 3

Background and Rationale:

Coronavirus disease 2019 (COVID-19) is an ongoing global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and at present with limited proven treatment.

Imatinib is a tyrosine kinase inhibitor that has been approved for treatment of many hematologic and solid neoplasms. Imatinib is a weak base that compared to the extracellular compartment is enriched over 1000-fold in the lysosome within several hours as a result of its lysosomotropic property. Accumulation of imatinib as a weak base in lysosomes may result in some antiviral activities by lysosomal alkalization required for virus/cell fusion.

Imatinib demonstrated *in vitro* activity against SARS-CoV viruses. Imatinib inhibits SARS-CoV and MERS-CoV with micromolar EC₅₀s (range, 9.8 to 17.6 μ M) with low toxicity. The mechanism of action studies suggested that ABL-1 tyrosine kinase regulates budding or release of poxviruses and Ebola virus, demonstrating that the c-ABL-1 kinase signaling pathways play an important role in the egress of these viruses. It is also reported that kinase signaling may also be important for replication of two members of the Coronaviridae family, SARS-CoV and MERS-CoV. *In vivo* studies performed in the mouse model of vaccinia virus infection showed that imatinib was effective in blocking dissemination of the virus.

Imatinib has anti-inflammatory activity including its effectiveness in a “two-hit” murine model of acute lung injury (ALI) caused by combined lipopolysaccharide (LPS) and ventilator-induced lung injury (VILI). Imatinib significantly decreased bronchoalveolar lavage protein, total cells, neutrophils, and TNF α levels in mice exposed to LPS plus VILI, indicating that it attenuates ALI in this clinically relevant model. In another experiment, imatinib attenuated ALI when given 4 hours after LPS, suggesting potential efficacy when given after the onset of injury. Overall, these results strongly suggest the therapeutic potential of imatinib against inflammatory vascular leak and a potential role of imatinib therapy for patients with acute respiratory distress syndrome (ARDS) on mechanical ventilation.

We *hypothesized* that addition of imatinib to the best conventional care (BCC) improves the outcome of hospitalized adult patients with COVID-19. This hypothesis is on the bases of 1) intralysosomal entrapment of imatinib will increase endosomal pH and effectively decrease SARS-CoV-2/cell fusion, 2) kinase inhibitory activity of imatinib will interfere with budding/release or replication of SARS-CoV-2, and 3) because of the critical role of mechanical ventilation in the care of patients with ARDS, imatinib will have a significant clinical impact for patients with severe COVID-19 infection in intensive care unit (ICU).

Target Population:

Hospitalized adult patients with COVID-19

Hypothesis:

Addition of imatinib to the BCC will provide a superior clinical outcome for patients with COVID-19 compared with BCC plus placebo

Primary Objectives

To evaluate the efficacy, safety, and tolerability of imatinib compared with placebo in combination with the BCC in adults hospitalized with COVID-19

Primary Endpoint

The primary endpoint is all-cause mortality at Day 28 after the start of imatinib/placebo.

Secondary Endpoints

- All-cause mortality at Day 60 after the start of imatinib/placebo
- The proportion of patients with a two-point improvement at Day 14 from baseline using the 8-category ordinal scale. The ordinal scale is an evaluation of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen – no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death
- Time to a 2-point clinical improvement difference over baseline
- Duration of hospitalization
- Duration of ECMO or invasive mechanical ventilation (for participants who are on ECMO or mechanical ventilation at Day 1)
- Duration of ICU stay (for participants who are in ICU at Day 1)
- Proportion of participants with negative oropharyngeal or nasopharyngeal swab for SARS-CoV-2 by quantitative RT-PCR on days 14 and 28 after starting treatment
- Proportion of participants with serious adverse events
- Proportion of participants who discontinue study drug due to adverse events

Study design

- This is an individual patient-level randomized, double-blind, placebo-controlled phase 3 study to evaluate the safety and efficacy of imatinib for the treatment of hospitalized adults with COVID-19. Participants will be followed for up to 60 days from start of study drug administration. Eligible patients will be randomized in 2:1 (imatinib/placebo) ratio to receive either imatinib or placebo for 14 days. Both groups will receive the best conventional care (BCC, detailed in Section 1.6).
- In order to balance the severity of the respiratory illness between the two arms, per FDA recommendation randomization will be stratified based on radiographic findings and oxygen requirements:
 - 1) **Severe disease:** evidence of pneumonia on chest X-ray or CT scan or chest auscultation (rales, crackles), and $\text{SpO}_2 \leq 92\%$ on ambient air or $\text{PaO}_2/\text{FiO}_2 < 300$ mmHg, and requires supplemental oxygen administration by nasal cannula, simple face mask, or other similar oxygen delivery device
 - 2) **Critical disease:** requires supplemental oxygen delivered by non-rebreather mask or high flow cannula or use of invasive or non-invasive ventilation or requiring treatment in an ICU, use of vasopressors, or extracorporeal life support.
- This trial will be conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonization.

Sample Size

The trial is designed as a double-blind, two-parallel arm, randomized controlled study with a 1:1 allocation ratio to: Arm A) imatinib or Arm B) placebo. Patients in both arms will receive the best conventional care (BCC) per local institutional standards at the discretion of the treating physician.

Group sample sizes of 173 in Arm A and 173 in Arm B achieve 80% power to detect a difference between the mortality in the two trial arms of 0.10. The proportion in Arm A (imatinib treatment arm) is assumed to be 0.10 under the null hypothesis and 0.20 under the alternative hypothesis. The proportion in Arm B (placebo control arm) is 0.10. The test statistic used is the one-sided Fisher's Exact Test. The significance level of the test is targeted at 0.05. The significance level actually achieved by this design is $\alpha=0.0385$. The power of the test is calculated using binomial enumeration of all possible outcomes.

The primary analysis will be conducted using an intention to treat principle (ITT) for participants who at least receive one dose of study drug or placebo. The sample size is not inflated for dropouts. All patients will be evaluable irrespective of the clinical course of their disease.

Key Eligibility Criteria

Inclusion Criteria

Patients may be included in the study only if they meet **all** of the following criteria:

- Ability to understand and willingness to sign a written informed consent document. Informed consent must be obtained prior to participation in the study. For patients who are too unwell to provide consent such as patients on invasive ventilator or ECMO, Legally Authorized Representative (LAR) can sign the informed consent.
- Hospitalized patients ≥ 18 years of age
- Positive RT-PCR assay for SARS-CoV-2 in the respiratory tract sample (oropharyngeal, nasopharyngeal or BAL) by outside or local laboratory within 7 days of randomization

Exclusion Criteria

Patients meeting any of the following criteria are **not** eligible for the study:

- Patients receiving any other investigational agents in a clinical trial. Off-label use of agents such as hydroxychloroquine, remdesivir, or immunomodulators is not an exclusion criterion.
- Pregnant or breastfeeding women
- Patients with significant liver dysfunction function at screen as defined as:
 - Total bilirubin > 2.5 mg/dL
 - ALT > 5 x upper limit of normal
- Patients with significant hematologic disorder at screen as defined as:
 - Absolute neutrophil count (ANC) $< 200/\mu\text{L}$
 - Platelet $< 20,000/\mu\text{L}$
 - Hemoglobin < 7 g/dL
- Uncontrolled undercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled active seizure disorder, or psychiatric illness/social situations that per site Principal Investigator's judgment would limit compliance with study requirements
- Known allergy to imatinib or its component products
- Any other clinical conditions that in the opinion of the investigator would make the participant unsuitable for the study

Study Treatments: Imatinib oral 400 mg daily or placebo for 14 days

Study Centers: University of Maryland Medical Center (UMMC), Baltimore, MD is the initiating site. The study may be opened in up to 15 more centers including but not limited to University of Maryland Medical System (UMMS) hospitals across the United States and other countries on the bases of the accrual rate or the magnitude of COVID-19 pandemic.

We are aware of the enrollment requirement of ~350 patients, which is required to provide scientific integrity of the results. We are also aware of the fact that enrolling this number of patients in a single-site at UMMC may take longer than expected particularly taken into account other competing studies. For this reason, we actively consider to open the study in other sites. After identification of other sites, we will fulfill all regulatory requirements before enrolling patients in other sites.

Schedule of Activities

ASSESSMENTS/ OBSERVATIONS	Screen (D-3 to D1)	Day 1	Day 2	Day 5	Day 8	Day 10	Day 14 ^a	Day 21 ^j	Day 28 ^j	Day 60 ^{b,j}
		±2 d	±2 d	±2 d	±2 d	±2 d	±2 d	±7 d	±7 d	±7 d
Informed consent	X									
Confirm eligibility	X	X								
Randomization		X								
Study drug administration ^c		X								
Demographics	X									
Medical history	X									
Vital signs & Physical exam ^d	X	X		X		X	X	X	X	X
Clinical assessments ^e	X	X								
CBC with differential count	X		X	X		X	X		X	X
Chemistries ^{f,g}	X		X	X		X	X		X	X
CRP ^g	X			X			X		X	X
ECG	X									
Pregnancy test	X									
Targeted AE assessment		X								
Concomitant medication	X	X		X		X	X	X	X	X
Primary endpoint assessment							X			
SARS-CoV-2 PCR ^{h,i}	X	X		X		X	X		X	
Correlative/scientific studies ⁱ		X					X		X	

Screen (Day -3 to Day 1) - Screening and Day 1 visits can occur the same day.

^a Early discharge visit - use Day 14 assessments

^b Early termination visit - use Day 60 assessments

^c For planned 14 days

^d Clinically appropriate physical exams including vital signs and O₂ saturation

^e Clinical assessments: 8-point ordinal scale and respiratory treatment status. Daily while hospitalized.

^f Chemistries include the following: sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, calcium, magnesium, phosphorous, AST, ALT, total bilirubin, alkaline phosphatase, albumin, total protein, and LDH. If total bilirubin is elevated, then fractionated direct bilirubin can be measured. Amylase, lipase, coagulation factors, and uric acid are measured at the discretion of the investigators. Check D-dimer and ferritin levels when clinically indicated.

^g Missing lab tests of LDH, magnesium and phosphorous at the time points designated may be permissible as this does not affect either patient safety or scientific integrity of the protocol

^h Respiratory specimens (nasopharyngeal or oropharyngeal swabs).

ⁱ Missed correlative samples may be permissible when patients are enrolled on Holidays or access to patients is limited

^j Optional visits will occur starting after Day 14/early discharge. Please refer to section 7.5

Study Glossary

AE	Adverse Event
ALP	Alkaline Phosphatase
ALT	Alanine Aminotransferase
ANC	Absolute Neutrophil Count
AST	Aspartate Aminotransferase
BCC	Best Conventional Care
BP	Blood Pressure
CBC	Complete Blood Count
CFR	The Code of Federal Regulations
CI	Confidence Interval
CNS	Central Nervous System
CRF	Case Report Form
CRP	C Reactive Protein
CRS	Cytokine Release Syndrome
CTCAE	Common Terminology Criteria for Adverse Events
DOR	Duration Of Response
DSM	Data and Safety Monitoring
ECG	Electrocardiogram
eCRF	Electronic Case Report Form
FDA	Food and Drug Administration
FDAAA	Food and Drug Administration Amendments Act
FDAMA	Food and Drug Administration Modernization Act
GCP	Guideline for Good Clinical Practice
h, hr	Hour
Hgb	Hemoglobin
HR	Heart Rate
ICF	Informed Consent Form
ICH	International Conference on Harmonization
ICJME	International Committee of Medical Journal Editors
IND	Investigational New Drug
IPIM	Investigational Product Instructional Manual
IRB	Institutional Review Board
IV	Intravenous
LDH	Lactate Dehydrogenase
MHC	Major Histocompatibility Complex
mL	microliter
mg	Milligrams
MOI	Multiplicity Of Infection
N, n	Number
OS	Overall Survival
PBMC	Peripheral Blood Mononuclear Cells
PK	Pharmacokinetic
PCR	Polymerase Chain Reaction
QAC	Quality Assurance Committee
RT-PCR	Reverse-Transcriptase Polymerase Chain Reaction
RBC	Red Blood Cell
SAE	Serious Adverse Event
SD	Standard Deviation
SEM	Standard Error of Mean
SFU	Safety Follow-UP
SOC	Standard Of Care
TBL	Total Bilirubin
VPN	Virtual Protected Network
WBC	White Blood Cell
WHO	World Health Organization

Table of Contents

Key Personnel	2
Protocol Synopsis	3
Schedule of Activities.....	7
Study Glossary	8
1. BACKGROUND, CONCEPT AND RATIONAL	11
1.1. COVID-19.....	11
1.2. Imatinib and lysosomal Sequestration	11
1.3. Anti-Viral Activity of Imatinib.....	12
1.4. Anti-Inflammatory Activity of Imatinib.....	13
1.5. Rationale: Imatinib for Treatment of COVID-19	16
1.6. Best Conventional Care	19
2. OBJECTIVES AND ENDPOINTS	19
2.1. Primary Objectives	19
2.2. Primary Endpoint	19
2.3. Secondary Endpoints.....	19
2.4. Exploratory Endpoints.....	20
3. CRITERIA FOR STUDY PARTICIPANT ELIGIBILITY	20
3.1. Inclusion Criteria	20
3.2. Exclusion Criteria.....	20
3.3. Inclusion of Women and Minorities	21
4. RECRUITMENT PLAN AND REGISTRATION PROCEDURES	21
5. EXPERIMENTAL PLAN	22
5.1. Study Design.....	22
5.2. Study Drugs	22
5.3. Replacement of Participant	24
5.4. Estimated Study Duration and End of Study.....	24
6. DOSE MODIFICATION AND STUDY DISCONTINUATION.....	24
6.1. Dose Modification and Interruption	24
6.2. Study Discontinuation	24
7. STUDY ASSESSMENTS/PROCEDURES	25
7.1. Informed Consent and Demographics.....	25
7.2. Medical History.....	25
7.3. General Physical Examination.....	25
7.4. Laboratory Assessments	26
7.5. Optional Visits	26
7.6. Schedule of Assessments (Study Calendar).....	26

8.	REPORTING ADVERSE EVENTS / REGULATORY REQUIREMENTS	27
8.1.	Definitions	27
8.2.	Reporting of Adverse Events	27
8.3.	Reporting of Serious Adverse Events	28
8.4.	Data Safety Monitoring Plan	29
8.5.	Compliance with Laws and Guidance	29
8.6.	Institutional Review Board (IRB)	29
8.7.	Clinical Trial Monitoring	29
8.8.	FDA Reporting	30
8.9.	Records Retention	30
8.10.	Compliance with Trial Registration and Results Posting Requirements	30
8.11.	Data Management	30
9.	ADMINISTRATIVE AND LEGAL OBLIGATION	30
9.1.	Protocol Amendments and Study Termination	30
9.2.	Investigator Responsibilities for Data Collection	31
9.3.	Language	31
9.4.	Publication Policy	31
9.5.	Compensation	31
10.	STATISTICAL CONSIDERATIONS	31
10.1.	Randomization	31
10.2.	Primary endpoint	32
10.3.	Sample size estimation and power	32
10.4.	Secondary endpoints	32
10.5.	Interim analysis	32
10.6.	Safety profile	32
10.7.	Analysis of Efficacy Endpoints	32
11.	CORRELATIVE SCIENTIFIC STUDIES	33
11.1.	Viral Shedding	33
11.2.	Peripheral blood collection	33
11.3.	Serology	33
12.	REFERENCES	33

1. BACKGROUND, CONCEPT AND RATIONAL


1.1. COVID-19

A novel coronavirus, called SARS-CoV-2, has caused a pandemic of respiratory illness termed COVID-19.^{1,2} By April 24th 2020, approximately 2,800,000 confirmed cases are reported from 187 countries, areas or territories with approximately 194,000 confirmed deaths.³ In the US, there are ~900,000 confirmed cases with ~50,000 deaths.³ The clinical manifestation of COVID-19 ranges from self-limiting and mild respiratory tract illness in approximately 80% of cases to progressive pneumonia, multi-organ failure, and death.^{4,5} Although several groups around the globe are actively working on development of treatment(s) for COVID-19; to date, no specific small molecule, biologics including monoclonal antibodies, or vaccine has been approved for this viral disease.

1.2. Imatinib and lysosomal Sequestration

Imatinib mesylate is a small molecule kinase inhibitor approved by the FDA for the treatment of patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML), Ph+ acute lymphoblastic leukemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor), systemic mastocytosis (SM) without the D816V c-Kit mutation, hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR α fusion kinase, unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans, Kit (CD117) positive unresectable and/or metastatic as well as adjuvant treatment of malignant gastrointestinal stromal tumors (GIST).

Imatinib film-coated tablets contain imatinib mesylate equivalent to 100 mg or 400 mg of imatinib free base. Imatinib mesylate is designated chemically as 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate and its structural formula is:



Imatinib mesylate is soluble in aqueous buffers \leq pH 5.5 but is slightly soluble to insoluble in neutral/alkaline aqueous buffers. Lysosomal sequestration and accumulation of weak base tyrosine kinase inhibitors (TKIs) including imatinib has been reported by several groups.⁶⁻⁹




Figure 1. Weak-base drug distribution with lysosomal sequestration, uncharged molecules can freely diffuse across the lysosomal and plasma membranes while protonated (charged) molecules are trapped inside the acidic environment of lysosomes¹⁰

In a study using fluorescent microscopy to establish subcellular localization of imatinib, the investigators reported high intracellular uptake and retention (IUR) of imatinib in different cell lines.¹¹ The IUR of imatinib was time-, dose-, temperature-, and energy-dependent suggesting that plasma membrane imatinib transporters do not substantially contribute to the IUR of imatinib. Importantly, co-exposure with weak bases such as prazosin, amantadine, and NH₄Cl significantly altered the IUR of imatinib, likely due to lysosomal retention and accumulation of imatinib. Co-staining experiments with LysoTracker Red confirmed lysosomal sequestration of imatinib. The authors concluded that intracellular imatinib levels are primarily determined by lysosomal sequestration of imatinib and do not depend on the expression of imatinib transporters on plasma membrane.¹¹

In another study, the investigator reported the direct label-free visualization and quantification of imatinib inside living cells using hyperspectral stimulated Raman scattering imaging.¹² Compared to the extracellular drug, imatinib was enriched over 1000-fold in the lysosome within several hours as a result of its lysosomotropic property. Co-administration of imatinib with high dose chloroquine alkalinized intralysosomal vesicle, slightly (~5-fold) decreased intralysosomal concentration of imatinib but did not change the intralysosomal concentration of chloroquine.¹² This study confirmed the accumulation and intracellular drug-drug interaction of weak bases such as imatinib and chloroquine with label-free imaging.

1.3. Anti-Viral Activity of Imatinib

Imatinib mesylate is a known inhibitor of the Abelson murine leukemia viral oncogene homolog 1 (ABL1) pathway. The ABL1 pathway is a signaling pathway involved in cell differentiation, cell adhesion, and the cellular stress response. Overactivation of the ABL1 pathway can lead to CML. Imatinib mesylate inhibit SARS-CoV and MERS-CoV with micromolar EC₅₀s (range, 9.8 to 17.6 μ M) and low toxicity (Figure 2).¹³ SARS-CoV does appear to be more sensitive to the ABL1 inhibitor than MERS-CoV.

Imatinib mesylate has been reported to block egress of Ebola virus and of poxviruses and entry of coxsackievirus.¹⁴⁻¹⁶ These data suggest that the ABL1 pathway may be important for replication of many different virus families and, therefore, inhibitors of this pathway have the potential to be broad-spectrum antivirals.¹³ Mechanism of action studies showed that ABL1

tyrosine kinase controls budding or release of poxviruses and Ebola virus, demonstrating that the c-ABL1 kinase signaling pathways may play a role in the egress of these viruses. Frieman and his colleagues reported that “kinase signaling may also be important for replication of two members of the Coronaviridae family, SARS-CoV and MERS-CoV. Imatinib mesylate.”¹³ The step in viral replication in which these kinases are involved will need to be investigated further. *In vivo* studies performed in the mouse model of vaccinia virus infection demonstrated that imatinib mesylate was effective in blocking dissemination of the virus.¹⁶




Figure 2. Antiviral activity of imatinib mesylate. Vero E6 cells were infected with MERS-CoV or SARS-CoV at an MOI of 0.1 or 1, respectively, and treated for 48 h with eight doses of imatinib mesylate (B). Antiviral activity is shown in blue, and cytotoxicity is shown in red. EC₅₀s are indicated. Results are representative of one experiment (means SEM; n = 2).¹³

1.4. Anti-Inflammatory Activity of Imatinib

Anti-inflammatory activity of imatinib has been reported in preclinical and clinical settings. Amelioration of bleomycin-induced¹⁷ and radiation-induced¹⁸ pulmonary inflammation and fibrosis in mouse models were reported by imatinib as monotherapy or in combination with other agents. Wolf and colleagues provided strong evidence that imatinib has potent anti-inflammatory effects by reporting that it potently inhibited LPS- and Con A-induced TNF α production by human myeloid cells *in vitro* (peripheral blood mononuclear cells, CD14-selected monocytes, and monocyte-derived macrophages).¹⁹ Using several murine models of acute hepatitis, the investigator verified the *in vitro* findings, as imatinib prevented macrophage- and TNF α -dependent inflammatory damage of the liver induced by injection of either galactosamine or LPS by inhibition of hepatic TNF α production.¹⁹

Interestingly, and perhaps the most relevant to COVID-19-induced acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is the study performed by Rizzo and colleagues.²⁰ The investigators assessed the effectiveness of imatinib in a “two-hit” model of ALI caused by combined LPS and ventilator-induced lung injury (VILI), See Figures 2 and 3. Imatinib significantly decreased bronchoalveolar lavage protein, total cells, neutrophils, and TNF α levels in mice exposed to LPS plus VILI, indicating that it attenuates ALI in this clinically relevant model, See Figure 4.²⁰ In another experiment, imatinib attenuated ALI when given 4 hours after LPS, suggesting potential efficacy when given after the onset of injury.²⁰ Overall, these results strongly suggest the therapeutic potential of imatinib against inflammatory vascular leak and a potential role of imatinib combination therapy for patients with ARDS on mechanical ventilation.




Figure 3. Imatinib attenuates vascular leak in mice challenged with a 2-hit model of LPS and mechanical ventilation (MV). Mice were challenged with LPS [0.5 mg/kg, intratracheally (it)] ($t = 0$ h) and MV (respiratory rate 75, tidal volume 30 ml/kg, positive end-expiratory pressure 0 cm H₂O) ($t = 20$ –24 h) as outlined in *A*. Spontaneously breathing (SB) control mice received PBS (vs. LPS) and were intubated for 4 h without MV. Bronchoalveolar lavage (BAL) fluid, plasma, and lungs were harvested from the animals immediately after MV. Imatinib (IM) (75 mg/kg, ip) or vehicle was administered 0.5 h before LPS administration and before the initiation of MV. Lung permeability was assessed by BAL protein content (*B*), BAL fluid albumin (*C*), and lung tissue albumin (*D*). Additionally, in separate animals, Evans Blue dye (EBD) was injected (30 mg/kg, iv) 1 h before harvest, and representative extravasation into harvested lung tissue is shown (*E*) and quantified in multiple samples (*F*). The left lung of each of these animals was used for calculation of lung wet:dry ratio (*G*). SB ($n = 3$), SB + imatinib ($n = 3$), LPS + ventilator-induced lung injury (VILI) ($n = 3$ –11) and LPS + VILI + imatinib ($n = 3$ –6). * $P < 0.05$ compared with SB controls and # $P < 0.05$ compared with untreated animals.²⁰




Figure 4. Imatinib decreases lung inflammation in mice challenged with LPS and MV. Mice were subjected to the 2-hit lung injury model (LPS + VILI), and lung inflammation was quantified by BAL total cell counts (A) and BAL neutrophil counts (B). Representative hematoxylin and eosin (H and E)-stained lung sections are shown (C). Each H and E image was obtained from a different animal. SB (n = 3), SB + imatinib (n = 3), LPS + VILI (n = 3–11), and LPS + VILI + imatinib (n = 3–6). *P < 0.05 compared with SB controls and #P < 0.05 compared with untreated animals.²⁰




Figure 5. Imatinib decreases LPS-induced vascular leak when given after injury onset. Mice were challenged with LPS (1.0 mg/kg, it) (vs. PBS) and then received imatinib (75 mg/kg, ip) (vs. vehicle) 4 h later. Samples were harvested 18 h after LPS administration. Pulmonary vascular permeability was quantified in these animals by measuring BAL protein (A), BAL albumin (B), and lung tissue albumin (C). In separate animals, EBD was injected (30 mg/kg, iv) 1 h before harvest, and representative extravasation into harvested lung tissue is shown (D) and quantified in multiple samples (E). The left lung of each of these animals was used for calculation of lung wet:dry ratio (F). SB (n = 3), SB + imatinib (n = 3), LPS (n = 3–6), and LPS + imatinib (n = 3–6). *P < 0.05 compared with SB controls and #P < 0.05 compared with untreated animals.²⁰

1.5. Rationale: Imatinib for Treatment of COVID-19

Tolerable and efficacious treatment for patients with COVID-19 are a rapidly evolving therapeutic challenge and the need to develop novel and optimal regimens to treat infection or prevent progression to critical illness remains probably the most important medical challenge in early 2020 worldwide. There are numerous clinical trials currently ongoing across the globe

using/repurposing anti-virals, anti-malaria agents, cytokines, monoclonal antibodies and vaccines. In this protocol, and based on preclinical evidence, we aim to clinically examine the addition of imatinib to BCC for treatment of hospitalized patients with COVID-19 positivity.

Imatinib is a weak base that accumulates in lysosomes resulting in potential broad-spectrum antiviral activities by lysosomal alkalization required for virus/cell fusion of SARS-CoV.²¹ It is demonstrated that imatinib can be trapped intralysosomally and increase endosomal pH¹² necessary for SARS-CoV-2 cell/membrane fusion and replication. Moreover, imatinib has anti-inflammatory effect in acute lung injury. Because of the critical role of mechanical ventilation in the care of patients with ARDS, this can have a significant clinical impact for patients with severe COVID-19 infection in ICU.²⁰ Mechanistic studies in mouse lung tissue and human lung endothelial cells revealed that imatinib inhibits LPS-induced NF- κ B expression and activation, Figures 5 and 6.²⁰




Figure 6. Imatinib inhibits LPS-induced NF- κ B phosphorylation and nuclear translocation in vitro. Human pulmonary artery endothelial cells (HPAEC) were treated with imatinib (40 μ M, 60 min) and then challenged with LPS (1 μ g/ml, 0–60 min). Lysates were harvested for Western blots for phosphorylated NF- κ B p65 (S536), total NF- κ B p65 protein, I κ B, and actin and quantified by densitometry (A and B). HPAEC plated on glass coverslips were subjected to identical conditions, and immunofluorescence microscopy was conducted to determine the localization of total NF- κ B p65 protein (red). 4',6-diamidino-2-phenylindole (DAPI) (blue) was used to stain the nuclei (white arrows) (C). Data are representative of 3 independent experiments. *P < 0.05 compared with nonchallenged samples.²⁰




A**B****C**

Figure 7. Imatinib decreases NF- κ B expression in mouse lungs after LPS. Mice were challenged with LPS (1.0 mg/kg, it) (vs. PBS) and then received imatinib (75 mg/kg, ip) (vs. vehicle) 4 h later. Lung tissue homogenates were collected, subjected to Western blotting for total NF- κ B p65 protein, and quantified by densitometry (A and B). Lanes in A represent lung homogenates from individual animals. Representative immunohistochemistry images are shown for NF- κ B p65 taken by an individual blinded to experimental condition (C). * $P < 0.05$.²⁰

It is important to address the clinical safety and availability of imatinib. Imatinib is clinically available worldwide and have been in clinical practice for several years with very well-known adverse event profiles. It is tolerable as single-agent for patients with hematological disorders.^{22,23} Considering the half-life and other pharmacologic properties of imatinib, it is expected that the intended effect of the drug should be manifested by 14 days in this patient population.

1.6. Best Conventional Care

All participants will receive the best conventional care (BCC) available according to local practice standards. Taking into account that practice standards will evolve as data from multiple ongoing studies become available, BCC may change overtime. In this study the BCC may include, but is not limited to: use of antipyretics, anti-infectives including antivirals, anti-inflammatory agents, immunomodulators, supplemental oxygen, non-invasive and invasive ventilation, vasopressor support, renal-replacement therapy, and ECMO.

Therapies that are shown to be effective but may not be licensed will be added as an exception to the exclusion criteria in order to allow for the most contemporary standard of care to include emergency use authorization treatments as they become available. Antivirals such as remdesivir will be permissible given the FDA authorized emergency use.

2. OBJECTIVES AND ENDPOINTS

2.1. Primary Objectives

To evaluate the efficacy and safety of oral administration of imatinib combined with BCC vs. placebo plus BCC in hospitalized patients with COVID-19

2.2. Primary Endpoint

The primary endpoint is all-cause mortality at Day 28 after the start of imatinib/placebo.

2.3. Secondary Endpoints

- All-cause mortality at Day 60 after the start of imatinib/placebo
- The proportion of participants with two-point improvement at Day 14 from baseline using the 8-category ordinal scale. The ordinal scale is an evaluation of the status at the first assessment of a given study day. This endpoint of clinical improvement has been used before in clinical trials in patients hospitalized with severe influenza²⁴ and with COVID-19²⁵ infection, and it was recommended by the WHO R&D Blueprint expert group²⁶. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen – no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.
- Time to a 2-point clinical improvement difference over baseline
- Duration of hospitalization
- Duration of ECMO or invasive mechanical ventilation (for participants on ECMO of mechanical ventilation at Day 1)
- Duration of ICU stay/requirement (for participants in ICU at Day 1)
- Proportion of participants with treatment-related serious adverse events
- Proportion of participants who discontinue study treatment due to adverse events
- Proportion of patients with a negative oropharyngeal or nasopharyngeal swab for SARS-CoV-2 by quantitative RT PCR on days 14 and 28

2.4. Exploratory Endpoints

- Obtain blood/PBMCs for storage to look at transcriptomics in severe disease
- Association of MHC with severity of illness
- Mean change in the ordinal scale from baseline
- Time to an improvement of one category from admission using an ordinal scale
- Duration of hospitalization
- Duration of new oxygen use
- Number of oxygenation free days
- Duration of new mechanical ventilation
- Number of ventilator free days

3. CRITERIA FOR STUDY PARTICIPANT ELIGIBILITY

3.1. Inclusion Criteria

Patients may be included in the study only if they meet **all** of the following criteria:

1. Ability to understand and willingness to sign a written informed consent document. Informed consent must be obtained prior to participation in the study. For patients who are too unwell to provide consent such as patients on invasive ventilator or ECMO, Legally Authorized Representative (LAR) can sign the informed consent.
2. Hospitalized patients ≥ 18 years of age
3. Positive RT-PCR assay for SARS-CoV-2 in the respiratory tract sample (oropharyngeal, nasopharyngeal or BAL) by outside or local laboratory within 7 days of randomization.
4. Women of childbearing potential must agree to use at least one primary form of contraception for the duration of the study.

3.2. Exclusion Criteria

Patients meeting any of the following criteria are **not** eligible for the study:

1. Patients receiving any other investigational agents in a clinical trial. Off-label use of agents such as hydroxychloroquine, remdesivir, or immunomodulators is not an exclusion criterion.
2. Pregnant or breastfeeding women
3. Patients with significant liver dysfunction at screen as defined as:
 - a. Total bilirubin > 2.5 mg/dL
 - b. ALT > 5 x upper limit of normal
4. Patients with significant hematologic disorder at screen as defined as:
 - a. Absolute neutrophil count (ANC) $< 200/\mu\text{L}$
 - b. Platelet $< 20,000/\mu\text{L}$
 - c. Hemoglobin < 7 g/dL
5. Uncontrolled undercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled active seizure disorder, or psychiatric illness/social situations that per site Principal Investigator's judgment would limit compliance with study requirements.
6. Known allergy to imatinib or its component products
7. Any other clinical conditions that in the opinion of the investigator would make the participant unsuitable for the study.

3.3. Inclusion of Women and Minorities

Both men and women of all races and ethnic groups are eligible for this trial.

4. RECRUITMENT PLAN AND REGISTRATION PROCEDURES

Informed consent is a process that is initiated prior to the individual agreeing to participate in the study and continues throughout the individual's study participation. The informed consent form is IRB-approved and the participant will be asked to read and review the document. Due to the excessive risk of COVID-19 transmission and to preserve limited personal protective equipment (PPE) for essential procedures, a **remote consenting process** will be used. The following considerations for remote informed consenting should be followed:

- The investigator and/or his designee is responsible for presenting the risks and benefits of study participation to the patient in simple terms using the informed consent document.
- Potential participants will be given an informed consent form (either paper or electronic document in a portable electronic device) and allowed time to read this document.
- The elements of the informed consent, including discussion of the risk and benefits, will be done either over the phone or via remote video conferencing methods approved by the IRB.
- Research team member will document how the consent form was transmitted or given to participant, and what method was used to communicate the informed consent.
- The investigator will ensure that written informed consent is obtained from each participant or legally authorized representative by obtaining the appropriate signatures and dates on the informed consent document before the performance of protocol evaluations or procedures.
- Signatures may be obtained using the following options: (1) electronic signature, or (2) photograph of signature/signature page sent back to study team.
- Participants must date the informed consent form to be valid.
- Study team member should document how signature was obtained.

If unable to obtain a participant signature on an informed consent document, the following should be followed:

- Document the method used for communication with the participant
- Document means by which agreement was communicated;
- Document that no imaging technology was available to capture a signed consent form;
- A witness to the process and a witness sign and date the informed consent form.

Participants must be informed that participation is voluntary and that they may withdraw from the study at any time, without prejudice. Copies of the informed consent documents will be given to the participants for their records. The informed consent process will be conducted and documented in the source document (including the date) before the participant undergoes any study-specific procedures. The rights and welfare of the participants will be protected by emphasizing to them that the quality of their medical care will not be adversely affected if they decline to participate in this study.

For participants who are too unwell to provide consent such as participants on invasive ventilator or ECMO, Legally Authorized Representative (LAR) can sign the informed consent.

At the time of consent, a unique participant ID number will be assigned to the participant by UMMC. If for some reason the participant rescreens, the same participant ID number will be assigned to the participant for rescreening.

Once the signed informed consent has been obtained and all pretreatment evaluations have been performed, eligibility of the participant will be reviewed by the Lead Protocol Coordinator and the PI. Only eligible participants will be enrolled on the study.

The following documents will be compiled by the Lead Protocol Coordinator, PI, or other study team member for eligibility verification:

- Signed informed consent form (ICF)
- Copy of required laboratory tests including chemistry, CBC, bilirubin, LFT, RT-PCR assay results, and evidence of negative pregnancy test results for eligible participants
- Completed Eligibility worksheet

If the participant is deemed eligible for enrollment, the Lead Protocol Coordinator, PI, or other study team member will forward the completed packet to the Lead Data Manager (DM). The PI or sub-Is determine stratification and approves the start of treatment. The approval will be communicated to investigational drug service (IDS) pharmacy by the Lead Protocol Coordinator, PI, or other study team member, and IDS pharmacy will then randomize the patient. The participant will then be registered in OnCore and assigned a primary DM by the Lead DM.

Following enrollment, participants should begin protocol treatment within 3 days. Issues that would cause treatment delays should be discussed with the PI (Dr. Levine). If a participant does not receive protocol therapy following registration, the participant's registration on the study may be canceled.

5. EXPERIMENTAL PLAN

5.1. Study Design

This is an individual patient-level, randomized, double-blind, placebo-controlled phase 3 clinical trial at the University of Maryland Medical System, MD. Eligible patients are randomly assigned in 2 [imatinib] : 1 [placebo] ratio to receive either tyrosine kinase inhibitor imatinib or placebo for 14 days. In both arms, all study participants receive the best available conventional supportive care according to local practice standards. Taken into account that there are many national and international studies are ongoing, the BCC may change overtime. In this study the BCC may include, but not limited to, antipyretics, anti-infectives including antivirals (e.g. remdesivir), anti-inflammatory agents (e.g. chloroquine analogues, monoclonal antibodies, IL-6 receptor inhibitors, etc.), supplemental oxygen, non-invasive and invasive ventilation, vasopressor support, renal-replacement therapy, and ECMO. In both arms, participants can receive concomitant antibiotics at the discretion of the treating physician as necessary.

In order to balance the severity of the respiratory illness between the two arms, per FDA recommendation randomization are stratified based on radiographic findings and oxygen requirements: 1) Severe disease: evidence of pneumonia on chest X-ray or CT scan or chest auscultation (rales, crackles), and $SpO_2 \leq 92\%$ on ambient air or $PaO_2/FiO_2 < 300$ mmHg, and requires supplemental O_2 administration by nasal cannula, simple face mask, or other similar oxygen delivery device; 2) Critical disease: requires supplemental O_2 delivered by non-rebreather mask or high flow cannula or use of invasive or non-invasive ventilation or requiring treatment in an ICU, use of vasopressors, extracorporeal life support, or renal replacement therapy.

The trial is conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonization.

5.2. Study Drugs

Imatinib

All doses of imatinib should be administered with a meal and a large glass of water. Imatinib can be dissolved in water or apple juice for participants having difficulty swallowing. In this study, participants with confirmed COVID-19 positive tests receive imatinib for total of 14 days; 400 mg orally daily Days 1-14. Imatinib 400 mg tablets will be encapsulated using size 000 capsules and cellulose microcrystalline filler. For participants on ventilator or ECMO, imatinib will be given as oral suspension (40 mg/mL). To make the oral suspension, imatinib tablets will be crushed and mixed in Ora-sweet solution to yield a concentration of 40 mg/mL suspension by pharmacy. Additionally, in the absence of supportive microbiological testing results, we confirm that the in-use stability period for the prepared imatinib suspensions will be 24 h at room temperature or 7 days at refrigerated conditions.

Due to the COVID-19 crisis, healthcare professionals (nursing staff in particular) are faced with the major burden of caring for critically patients, such as those on ventilators or ECMO. We believe that it to be impractical to request nursing staff to prepare imatinib oral solution by immersing on the floor. Additionally, we also believe this practice could result in dosing errors if tablets are not fully dissolved and may compromise the medication during preparation. The local pharmacy staff will prepare imatinib oral suspension under hazardous hood with proper protected equipment, which is vented to outside and meet USP Pharmaceutical Compounding guidelines. Lastly, pharmacy staff will be educated regarding risk associated with crushing and handling of imatinib and required protective measures. The pharmacy staff will follow the American Society Health-System Pharmacists (ASHP) guidelines for handling hazardous drugs.

The pharmacokinetics (PK) of imatinib have been evaluated in studies in healthy participants and in population PK studies in over 900 participants. Imatinib is well absorbed after oral administration with C_{max} achieved within 2-4 h post-dose. Mean absolute bioavailability of imatinib is 98%. There is no significant change in the PK of imatinib on repeated dosing, and accumulation is 1.5- to 2.5-fold at steady state when imatinib is dosed once-daily. At clinically relevant concentrations of imatinib, binding to plasma proteins in *in vitro* experiments is approximately 95%, mostly to albumin and α_1 -acid glycoprotein.²³

For Warnings, Precautions, Drug interactions, and Geriatric use, see attached FDA Label for Imatinib dated 08/21/2018.

Placebo

The matching placebo will be packaged by the IDS Pharmacy of the site. The placebos will be prepared using size 000 capsules and cellulose microcrystalline filler. Imatinib 400 mg capsules and placebo capsules will be identical form and color. For participants on ventilator or ECMO, placebo will be given as oral suspension with similar process for making imatinib suspension.

Concomitant Medications/Supportive Care

In both arms, participants can receive concomitant available local standard of care antipyretics, antibacterials, antivirals, antifungals and anti-inflammatory agents at the discretion of the treating physician as necessary. For other drug-drug interaction particularly with CYP P450, the treating physician should consider risk and benefit of drug administration based on available information.

Co-administration of off-label immunomodulatory treatments for COVID-19 including but not limited to corticosteroids, sarilumab, clazakizumab, tocilizumab, and anakinra will be allowed but may affect interpretability of study outcomes. The timing, dosing, and duration of these treatments will be meticulously collected, including any of these treatments that may be used for participants who experience progression of COVID-19 disease after study enrollment. Two analyses will be performed, the primary analysis will compare the primary endpoint in the two

trial arms irrespective of any other treatment; the second analysis will be stratified for co-administration of immunomodulatory drugs.

Concomitant medications used in the management of targeted SAEs and/or targeted AEs will be collected and recorded in the electronic case report forms.

5.3. Replacement of Participant

The primary analysis will be conducted using a strict intention to treat principle (ITT). All participants will be evaluable irrespective of the clinical course of their disease and the dose of study medication received.

5.4. Estimated Study Duration and End of Study

For an individual participant the length of participation is approximately 60 days. Per recommendation by the FDA, we extend the duration of follow-up to Day 60 to assess adverse events and mortality. FDA recommended that telephone visits (or telemedicine) could be considered if clinic visits are not feasible.

End of Trial is defined as the time when the last participant is assessed or receives an intervention for the purposes of final data collection for the primary endpoint of the study. End of study for individual participant is defined as the last day that protocol-specified assessments are conducted for an individual participant.

6. DOSE MODIFICATION AND STUDY DISCONTINUATION

6.1. Dose Modification and Interruption

Participants can remain on the study if they at least receive 80% of pre-specified dosages of placebo or imatinib, i.e. participants may miss < 20% of the scheduled drug dosages for medical reason(s) (at the discretion of treating physician) or administrative reason(s) such as temporary unavailability of a drug for a specific dose/schedule or nursing/clerical errors. Participants remain in the ITT analysis irrespective of dosage received.

6.2. Study Discontinuation

Treatment should be discontinued in the event of any of the following:

- Occurrence of Grade 4 AE at least probably related to imatinib/placebo.
- Occurrence of an AE which makes discontinuation from treatment necessary due to protocol-specified safety criteria or desirable in the investigator's and/or the participant's opinion
- Investigator's decision that a change of therapy is in the participant's best interest
- Intercurrent medical condition, which in the opinion of the investigator or the participant precludes further treatment of the participant
- Withdrawal of participant's consent to further study treatment
- Death
- Lost to follow-up

All reasons for treatment discontinuation will be documented in the CRFs. If a participant fails to keep the appointments for study visits, the investigator will document the reason and circumstances as completely and accurately as possible.

Participants have the right to withdraw from the study at any time and for any reason without prejudice to his or her future medical care by the physician or at the institution.

Participants can decline to continue receiving protocol-specified therapies or procedures at any time during the study but continue participation in the study. If this occurs, the Investigator is to discuss with the participant the appropriate processes for discontinuation from protocol-

specified therapies and must discuss with the participant the options for continuation of the Schedule of Assessments and collection of data, including endpoints and AEs. The Investigator documents the change to the Schedule of Assessments and the level of follow-up that is agreed to by the participant (e.g., in person, through family/friends, in correspondence/communication with other physicians, from review of the medical records).

Withdrawal of consent for a study means that the participant does not wish to receive further protocol-specified therapies or procedures, and the participant does not wish to or is unable to continue further study participation. Participant data up to withdrawal of consent will be included in the analysis of the study, and where permitted, publically available data can be included after withdrawal of consent. Per recommendation by FDA, multiple attempts will be made to obtain final outcomes on all participants enrolled. The primary endpoint can be assessed without any diagnostic tests or imaging and we expect essentially all participants to be evaluable with respect to this endpoint. The only exception is in case a participant wants to withdraw from the study and demands that his/her data not be used. We expect this to be an exceptional situation.

7. STUDY ASSESSMENTS/PROCEDURES

7.1. Informed Consent and Demographics

All participants must sign and date the most current IRB approved ICF. All enrolled participants should be re-consented with any updated versions of IRB approved ICF as applicable and per institutional guidelines.

Demographic data that will be collected include sex, date of birth, race, and ethnicity.

The following assessments/procedures are to be completed during the screening period: Confirmation that the ICF has been signed, Eligibility confirmed based on inclusion/exclusion criteria, Medical history, Demographic data collection, Pregnancy test, Local laboratory assessments including CBC with differential and Chemistry and CRP and ECG, Participant Registration. Subsequent ECGs will be obtained if clinically indicated at the discretion of the treating physician. FDA recommends clinically indicated ECGs given the risk of QT prolongation and overlapping cardiac risk profiles with some or the concomitant medications. Some of the screening assessments/procedures completed prior to consent can be used for study purposes since frequent access to COVID-19 patients is restricted for nursing safety. That assessments required at Screening if done within 7 days of consent will be accepted and there is no need to repeat these assessments.

7.2. Medical History

The Investigator or designee will collect relevant medical history before the start of study and with every AE reporting. All findings are recorded on the medical history CRF. Per FDA recommendation, the number of days between onset of symptoms and initiation of treatment will be collected.

7.3. General Physical Examination

If weight is not able to be obtained at the time of enrollment, self-reported weight is acceptable. The baseline physical examination will include as much physical examination as clinical condition of the participants allows. The physical examination at subsequent study visits will consist of an interim examination to monitor for any changes from the baseline physical examination. Physical examination does not have to be comprehensive and is determined by the treating physician. For vital signs, the following measurements must be performed as outlined in the Schedule of Assessments: systolic/diastolic blood pressure, pulse rate, respirations and O₂ saturation, and temperature in intervals.

7.4. Laboratory Assessments

Analyses for all laboratory tests used throughout this study are listed in the Study Calendar. All screening and on-study laboratory samples will be collected and processed at the investigators local laboratory and analyzed locally. If for clinical reason(s) or isolation status laboratory sampling cannot be performed, it does not considered protocol deviation.

Urine or serum pregnancy tests will be performed locally on all females except for female participants who are surgically sterile or > 2 years postmenopausal. If the pregnancy test is positive at screening the participant should not be enrolled. If a standard of care pregnancy test is collected during the study, and the result is positive, the treating physician should contact the principle investigator for instructions. If a female participant, or the partner of a male participant, becomes pregnant during the conduct of the study it must be reported on the UMB IRB Pregnancy Notification Worksheet.

7.5. Optional Visits

Day 21, Day 28, or Day 60 are optional in the event that participant is discharged prior to these visits. Depending when the participant is discharged, the Lead Protocol Coordinator will conduct a telephone call on Day 28 or Day 60 as a follow-up.

7.6. Schedule of Assessments (Study Calendar)

ASSESSMENTS/ OBSERVATIONS	Screen (D-3 to D1)	Day 1	Day 2	Day 5	Day 8	Day 10	Day 14 ^a	Day 21 ^j	Day 28 ^j	Day 60 ^{b,j}
		±2 d	±2 d	±2 d	±2 d	±2 d	±2 d	±7 d	±7 d	±7 d
Informed consent	X									
Confirm eligibility	X	X								
Randomization		X								
Study drug administration		X								
Demographics	X									
Medical history	X									
Vital signs & Physical exam ^d	X	X		X		X	X	X	X	X
Clinical assessments ^e	X	X								
CBC w diff count	X		X	X		X	X		X	X
Chemistries ^{f,g}	X		X	X		X	X		X	X
CRP ^g	X			X			X		X	X
ECG	X									
Pregnancy test	X									
Targeted AE assessment		X								
Concomitant medication	X	X		X		X	X	X	X	X
Primary endpoint assessment							X			
SARS-CoV-2 PCR ^{h,i}	X	X		X		X	X		X	
Correlative/scientific studies ⁱ		X					X		X	

Screen (Day -3 to Day 1) - Screening and Day 1 visits can occur the same day.

^a Early discharge visit - use Day 14 assessments

^b Early termination visit - use Day 60 assessments

^c For planned 14 days

^d Clinically appropriate physical exams including vital signs and O2 saturation

^e Clinical assessments - 7-point ordinal scale and respiratory treatment status. Daily while hospitalized.

^f Chemistries include the following: sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, calcium, magnesium, phosphorous, AST, ALT, total bilirubin, alkaline phosphatase, albumin, total protein, and LDH. If total bilirubin is elevated, then fractionated direct bilirubin can be measured. Amylase, lipase, coagulation factors, and uric acid are measured at the discretion of the investigators. Check D-dimer and ferritin levels when clinically indicated.

^g Missing lab tests of LDH, magnesium, phosphorous, and CRP at the time points designated may be permissible as this does not affect either patient safety or scientific integrity of the protocol.

^h Respiratory specimens (nasopharyngeal or oropharyngeal swabs)

ⁱ Missed correlative samples may be permissible when patients are enrolled on Holidays or access to patients is limited

^j Optional visits will occur starting after Day 14/early discharge. Please refer to section 7.5

8. REPORTING ADVERSE EVENTS / REGULATORY REQUIREMENTS

8.1. Definitions

Adverse Event (AE): An AE is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. The Investigator is responsible for ensuring that any AEs observed by the Investigator or reported by the participant are recorded in the participant's medical record.

CTCAE term (AE description) and Grade: The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for AE reporting. All appropriate treatment areas should have access to a copy of the CTCAE version 5.0. A copy of the CTCAE version 5.0 can be downloaded from the CTEP web site.

Attribution of the AE:

- Definite – The AE is clearly related to the study treatment.
- Probable – The AE is likely related to the study treatment.
- Possible – The AE may be related to the study treatment.
- Unlikely – The AE is doubtfully related to the study treatment.
- Unrelated – The AE is clearly NOT related to the study treatment.

The Definition of a Serious Adverse Event (SAE):

SAE is defined as any of the following:

- Any death that occurs while the participant is enrolled in the study or within 30 days of completing the study
- Immediately life-threatening AE
- Requires inpatient hospitalization
- Prolongation of an existing hospitalization
- Congenital anomaly/birth defect
- Medically important event
- Disability/incapacity (persistent or significant)

8.2. Reporting of Adverse Events

The PI is responsible for monitoring the safety of participants who have entered this study and for alerting the UMGCCC Data and Safety Monitoring and Quality Assurance Committee (DSM/QAC) as well as the FDA to any event that seems unusual, even if this event maybe considered an unanticipated benefit to the participant.

Only the following targeted AEs if not present at the baseline and occur at any time during the clinical study or within 30 days of receiving the last dose of study medication, whether or not related to the study drug/placebo, will be collected by the study team into the Case Report Forms.

Targeted AEs:

- Infections and infestations \geq Grade 3 events
- Deep Vein Thrombosis (DVT) and other thromboembolic event
- Disseminated intravascular coagulation (DIC)
- Cytopenia including anemia \geq Grade 3, thrombocytopenia \geq Grade 3, neutropenia \geq Grade 3
- Adult Respiratory Distress Syndrome (ARDS) and respiratory acidosis
- Significant pulmonary changes from baseline (as indicated in relevant Imaging)

- Significant new arrhythmia
- Decreased LVEF
- ALT increased \geq Grade 3, AST increased \geq Grade 3, Direct bilirubin increased \geq Grade 3
- Acute Kidney Injury, Significant creatinine increased \geq Grade 3
- Periorbital edema, lower extremity edema, pericardial effusion, pleural effusion

After a study participant's completion of or discontinuation from the study, the investigator remains responsible to follow, through an appropriate health care option, AEs that are serious or that caused the study participant to discontinue before completing the study.

8.3. Reporting of Serious Adverse Events

The following serious adverse experiences (SAEs) which occur at any time during the clinical study or within 30 days of receiving the last dose of study medication, whether or not related to the study drug, will be collected by the study team into the Case Report Forms.

Targeted SAEs:

- Infections and infestations \geq Grade 3 events
- Deep Vein Thrombosis (DVT)
- Disseminated intravascular coagulation (DIC)
- Thromboembolic event
- Anemia \geq Grade 3
- Thrombocytopenia \geq Grade 3
- Neutropenia \geq Grade 3
- Adult Respiratory Distress Syndrome (ARDS)
- Respiratory acidosis
- Significant pulmonary changes from baseline (as indicated in relevant Imaging)
- Significant new arrhythmia
- Decreased LVEF
- Alanine aminotransferase (ALT) increased \geq Grade 3
- Aspartate aminotransferase (AST) increased \geq Grade 3
- Blood bilirubin increased \geq Grade 2
- Acute Kidney Injury
- Significant creatinine increased \geq Grade 2
- Periorbital edema
- Lower extremity edema
- Pericardial effusion
- Pleural effusion

If the event meets the criteria for FDA mandatory IND safety reporting (serious + related + unexpected), the UMMC will report the event to the FDA using the MedWatch form (FDA Form 3500A). Events which are assessed as "unexpected fatal or life-threatening" should be reported to FDA as soon as possible, but no later than 7 calendar days following the initial receipt of the information. All other unexpected suspected SAEs suggesting significant risk to human participants should be reported to FDA no later than 15 calendar days following the initial receipt of the information.

After a study participant's completion of or discontinuation from the study, the investigator remains responsible to follow, through an appropriate health care option, AEs that are serious or that caused the study participant to discontinue before completing the study.

The procedure is as follows: All deaths should be reported immediately; If the SAE was unexpected and possibly, probably, or definitely related to the drug, the investigator or designee must initiate the reporting process within 24 h of being made aware of the event; The FDA is to be informed of any serious AEs in accordance with established guidelines using the standard MedWatch forms (FDA Form 3500A).

8.4. Data Safety Monitoring Plan

It is the responsibility of the PI to oversee the safety of the study. This safety monitoring will include careful assessment and appropriate reporting of AEs as noted above. This study will be monitored by the UMGCCC DSM/QAC and will follow the Data Safety and Monitoring Plan as outlined in the Clinical Investigator Handbook of the UMGCCC Clinical Research Office. The DSM/QAC will meet after each 25 participants are enrolled or every 6 months whichever comes sooner. AE profile of imatinib is well known. Due to the dynamic environment of best conventional care, defined halting rules may not apply to future best conventional care processes. Enrollment halting may occur by DSM/QAC based on interim/cumulative data for evidence of study-related AEs including anticipated toxicities, such as ECG parameters, SAEs and laboratory parameters. At the official request of the DSM/QAC, the study can be unblinded. This decision will be discussed by the PI and other investigators as well as with the regulatory agencies including UMB IRB and FDA.

8.5. Compliance with Laws and Guidance

This study is conducted in accordance with current U.S. FDA Regulations, Good Clinical Practices (GCPs) and International Council on Harmonization (ICH) E6 Guidelines. The investigator and their sub-investigators will sign financial disclosure forms prior to participating in the study and one year post end of study (21 CFR 54.1-54.6).

8.6. Institutional Review Board (IRB)

This protocol was submitted to and approved by the University of Maryland IRB. Study procedures began once IRB approval was secured. All amendments, instances of reportable new information (i.e. unanticipated problems, data breaches, etc.) and continuing review reports will be submitted to the University of Maryland IRB per institutional policy.

8.7. Clinical Trial Monitoring

Source Data verification monitoring will be conducted in accordance with the Greenebaum Comprehensive Cancer Center Sponsor-Investigator Monitoring Standard Operating Procedure (SOP), the Code of Federal Regulations (CFR), and FDA and ICH E6 Guidelines. This will include central verification of eligibility of each participant enrolled and risk based monitoring strategies.

The Investigator and study staff are responsible for maintaining a comprehensive and centralized filing system of all study-related (essential) documentation, suitable for inspection at any time by representatives from UMGCCC and/or applicable regulatory authorities.

Elements to include are participant files containing ICFs and participant identification list, study files containing the protocol with all amendments, copies of pre-study documentation, and all correspondence to and from the IRB, Investigational product-related correspondence including Proof of Receipts (POR), Investigational Product Accountability Record(s), Return of Investigational Product for Destruction Form(s), Final Investigational Product Reconciliation Statement, as applicable. In addition, all original source documents supporting entries in the CRFs must be maintained and be readily available.

The Clinical Monitor is responsible for verifying the CRFs at regular intervals throughout the study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research. The Clinical Monitor is to have access to participant medical records and other study-related records needed to verify the entries on the CRFs.

The Investigator agrees to cooperate with the Clinical Monitor to ensure that any problems detected during these monitoring visits, including delays in completing CRFs, are resolved.

8.8. FDA Reporting

The FDA Annual Report will be submitted to the Agency within +/- 60 days of the date on the IND approval letter. Major amendments will be submitted to FDA at the time of IRB submission. Minor amendments will be reported to FDA at the time of the next major amendment or at the next FDA Annual Report (whichever comes first).

8.9. Records Retention

Essential documents should be retained until at least 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product. Records and documents pertaining to the conduct of this study and the distribution of investigational drug, including CRFs, ICFs, laboratory test results, and medication inventory records will be maintained in secure offsite storage after completion of study follow-up and data analysis.

8.10. Compliance with Trial Registration and Results Posting Requirements

Under the terms of the Food and Drug Administration Modernization Act (FDAMA) and the Food and Drug Administration Amendments Act (FDAAA), Dr. Levine submitted the protocol to the Clinical Trials Data Bank, <http://www.clinicaltrials.gov> and received the identifier NCT: 04394416.

8.11. Data Management

Source documents are original documents, data, and records from which the participant's CRF data are obtained. These include but are not limited to hospital records, clinical and office charts, laboratory and pharmacy records, diaries, radiographs, and correspondence.

Clinical data will be entered into the OnCore® database either by remotely accessing OnCore® via Virtual Protected Network (VPN) or by the designated data manager at the UMGCCC. OnCore® is 21CFR11.10 (electronic medical records) compliant and is equipped for HIPAA compliant internet-based entry of protocol tracking and review information.

All study data will be collected by the research team at each and every study visit and recorded in the research record. This data will then be entered in to the OnCore® study database.

All source documents will be obtained and retained along with any study forms, and placed into the participant's research folder.

9. ADMINISTRATIVE AND LEGAL OBLIGATION

9.1. Protocol Amendments and Study Termination

If the PI or other investigators wish to amend the protocol, the IRB must be informed of all amendments and give approval. The Investigator must send a copy of the approval letter from the IRB to UMGCCC. Significant changes will be reviewed by the FDA as well.

The Investigator is to notify the IRB in writing of the study's completion or early termination.

9.2. Investigator Responsibilities for Data Collection

The Investigator is responsible to comply with the requirements for all assessments and data collection (including participants not receiving protocol-specified therapies) as stipulated in the protocol for each participant in the study. For participants who withdraw before completion of all protocol-required visits and are unable or unwilling to continue the Schedule of Assessments, the Investigator can search publically available records [where permitted] to ascertain survival status. This ensures that the data set(s) produced as an outcome of the study is/are as comprehensive as possible.

9.3. Language

CRFs must be completed in English. All written information and other material to be used by participants and investigative staff must use vocabulary and language that are clearly understood.

9.4. Publication Policy

Authorship of any publications resulting from this study will be determined based on the: (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; (3) final approval of the version to be published; (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. If a multicenter group has conducted the work, the group is to identify the individuals who accept direct responsibility for the manuscript. These individuals are to fully meet the criteria for authorship defined above. All persons designated as authors are to qualify for authorship, and all those who qualify are to be listed. Authors are required to meet standard ICMJE criteria.

Acquisition of funding, collection of data, or general supervision of the research group, alone, does not justify authorship. Each author is to have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

9.5. Compensation

Any arrangements for compensation to participants for injury or illness that arises in the study are described in the ICF and is available as a separate document.

10. STATISTICAL CONSIDERATIONS

10.1. Randomization

The trial is designed as a placebo-controlled, double-blind, two-parallel arm, randomized trial with a 1:1 allocation ratio to:

Arm A) Imatinib+BCC

Arm B) Placebo+BCC

Participants in both arms can receive the supportive care per local standards at the discretion of the treating physician. Randomization will be completed centralized. Concealed randomization will be executed by the UMGCCC Pharmacist. Data on eligible consented cases will be submitted electronically on the appropriate on-study form to the pharmacy, where the participant is randomized to imatinib or placebo. The randomized treatment allocations use

stratified, permuted block randomization with a variable block size; blocks are generated using a validated random number generator.

10.2. Primary endpoint

The primary endpoint is all-cause mortality at Day 28 after the start of imatinib/placebo.

10.3. Sample size estimation and power

Group sample sizes of 173 in Arm A and 173 in Arm B achieve 80% power to detect a difference between the mortality in the two trial arms of 0.10. The proportion in Arm A (imatinib treatment arm) is assumed to be 0.10 under the null hypothesis and 0.20 under the alternative hypothesis. The proportion in Arm B (placebo control arm) is 0.10. The test statistic used is the one-sided Fisher's Exact Test. The significance level of the test is targeted at 0.05. The significance level actually achieved by this design is $\alpha=0.0385$. The power of the test is calculated using binomial enumeration of all possible outcomes

The sample size is not inflated for dropouts. All participants will be evaluable irrespective of the clinical course of their disease. The primary analysis will be conducted using an intention to treat principle (ITT) for participants who at least receive one dose of study drug or placebo. The sample size is not inflated for dropouts..

10.4. Secondary endpoints

1) all-cause mortality at Day 60 after the start of imatinib/placebo; 2) the proportion of patients with a two-point improvement at Day 14 from baseline using the 8-category ordinal scale; 3) time to a 2-point clinical improvement difference over baseline; 4) duration of hospitalization; 5) duration of ECMO or invasive mechanical ventilation (for participants who are on ECMO or mechanical ventilation at Day 1); 6) duration of ICU stay (for participants who are in ICU at Day 1); 7) proportion of participants with negative oropharyngeal or nasopharyngeal swab for SARS-CoV-2 by quantitative RT-PCR on days 14 and 28 after starting treatment; 8) proportion of participants with serious adverse events; 9) proportion of participants who discontinue study drug due to adverse events.

10.5. Interim analysis

No interim analysis for efficacy is planned. All grade 4 and 5 toxicities will be reported within 24 hours to an independent DSMB. The DSMB will decide if early stopping due to unacceptable toxicity is necessary.

10.6. Safety profile

A full safety profile will be reported with severity graded according to CTCAE, attribution to treatment, duration and time to resolution of toxicity. The safety population consists of all individual who received at least one dose of study medication.

10.7. Analysis of Efficacy Endpoints

Efficacy endpoint will be analyzed using the 1-sided Fisher's Exact Test. Response rates and the difference in response rates between trial arms will be estimated with 95% CI.

8-category ordinal scale

- 1) Not hospitalized, no limitations on activities
- 2) Not hospitalized, limitation on activities and/or requiring home oxygen
- 3) Hospitalized, not requiring supplemental oxygen – no longer requires ongoing medical care
- 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)
- 5) Hospitalized, requiring supplemental oxygen
- 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices
- 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
- 8) Death

11. CORRELATIVE SCIENTIFIC STUDIES

11.1. Viral Shedding

Viral shedding will be determined by testing eluate from oropharyngeal or nasopharyngeal swab using RT-PCR). The swabs will be stored at -80°C until use. Each sample will be tested in duplicate according to established protocol for SARS-CoV-2 in a CLIA-certified laboratory. Per FDA recommendation, “we will consider conducting genotypic resistance testing to examine the ability of SARS-CoV-2 to develop resistance to the study drugs when viral rebound is observed during the study. Regions including the receptor binding domain and the S1/S2 proteolytic cleavage sites in the S protein of SARS-CoV-2 may be of interest.”

11.2. Peripheral blood collection

Approximately 30-50 ml of peripheral blood (if possible) at different time points per Study Calendar will be acquired by phlebotomy. PBMC will be isolated. The plasma will be stored at -80°C. Cytokine response will be evaluated using Cytokine & Chemokine 34-Plex Human ProcartaPlex™ Panel 1A (ThermoFisher Scientific, Cat#EPX340-12167-901). A Luminex® 200 Instrument (LX-200) will be used to measure the cytokine concentration in plasma. Per FDA recommendation, we will try to determine SARS-CoV-2 RNA in collected blood samples.

11.3. Serology

Plasma will be used to determine the anti-SARS-Cov2 spike protein IgG and IgM levels by ELISA as well as IL-6. Purified spike protein will be coated in 96-well plates and incubated with serial dilution of participant plasma. As negative control plasma from pre-COVID-19 healthy individuals will be used. The antibodies will be detected using HRP-conjugated anti-hu-IgG and IgM antibodies followed by TMB reagent. The dilution at which the signal is reduced by 50% compared to maximum signal will be reported as EC₅₀.

12. REFERENCES

1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;395:507-13.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
3. World Health Organization (WHO). Coronavirus disease (COVID-19) Pandemic. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019> 2020.
4. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J (Engl)* 2020.
5. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA : the journal of the American Medical Association* 2020.
6. Chapuy B, Panse M, Radunski U, et al. ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. *Haematologica* 2009;94:1528-36.
7. Gotink KJ, Broxterman HJ, Labots M, et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2011;17:7337-46.
8. Gotink KJ, Rovithi M, de Haas RR, et al. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. *Cell Oncol (Dordr)* 2015;38:119-29.
9. Colombo F, Trombetta E, Cetrangolo P, et al. Giant Lysosomes as a Chemotherapy Resistance Mechanism in Hepatocellular Carcinoma Cells. *PloS one* 2014;9:e114787.

10. Ruzickova E, Skoupa N, Dolezel P, Smith DA, Mlejnek P. The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance. *Biomolecules* 2019;9.
11. Burger H, den Dekker AT, Segeletz S, et al. Lysosomal Sequestration Determines Intracellular Imatinib Levels. *Molecular pharmacology* 2015;88:477-87.
12. Fu D, Zhou J, Zhu WS, et al. Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering. *Nat Chem* 2014;6:614-22.
13. Dylla J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. *Antimicrobial agents and chemotherapy* 2014;58:4885-93.
14. Garcia M, Cooper A, Shi W, et al. Productive replication of Ebola virus is regulated by the c-Abl tyrosine kinase. *Sci Transl Med* 2012;4:123ra24.
15. Coyne CB, Bergelson JM. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. *Cell* 2006;124:119-31.
16. Reeves PM, Smith SK, Olson VA, et al. Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases. *J Virol* 2011;85:21-31.
17. Chilakapati SR, Serasanambati M, Vissavajhala P, Kanala JR, Chilakapati DR. Amelioration of bleomycin-induced pulmonary fibrosis in a mouse model by a combination therapy of bosentan and imatinib. *Exp Lung Res* 2015;41:173-88.
18. Li M, Abdollahi A, Grone HJ, Lipson KE, Belka C, Huber PE. Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. *Radiat Oncol* 2009;4:66.
19. Wolf AM, Wolf D, Rumpold H, et al. The kinase inhibitor imatinib mesylate inhibits TNF- α production in vitro and prevents TNF-dependent acute hepatic inflammation. *Proceedings of the National Academy of Sciences of the United States of America* 2005;102:13622-7.
20. Rizzo AN, Sammani S, Esquinca AE, et al. Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. *Am J Physiol Lung Cell Mol Physiol* 2015;309:L1294-304.
21. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends* 2020;14:72-3.
22. Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. *Nat Rev Rheumatol* 2020;16:155-66.
23. FDA. Imatinib Label. Food and Drug Administration 2018;https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021588s053lbl.pdf.
24. Wang Y, Fan G, Salam A, et al. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection. *J Infect Dis* 2019.
25. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med* 2020.
26. WHO. Coronavirus disease (COVID-2019) R&D Blueprint. World Health Organization 2020;<http://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/>.